Synthetic Protocols Mutually
Applicable to 4-Oxoquinolines and 4-Oxo-1,8-naphthyridines: Synthesis
of 1-Aryl-2-substituted and 1-Aryl-3-fluoro-4-oxoquinolines and
4-Oxo-1,8-naphthyridines

Ken-ichiro Awasaguchi; Hiromi Hayashi; Hyouei Kawai; Hiroko Tominaga; Yuichiro Sato; Kazuya Hayashi; Yozo Todo

doi:10.1055/s-0031-1290079

LETTER

Synthetic Protocols Mutually Applicable to 4-Oxoquinolines and 4-Oxo-1,8-naphthyridines: Synthesis of 1-Aryl-2-substituted and 1-Aryl-3-fluoro-4-oxoquinolines and 4-Oxo-1,8-naphthyridines

Ken-ichiro Awasaguchi*, Hiromi Hayashi, Hyouei Kawai, Hiroko Tominaga, Yuichiro Sato, Kazuya Hayashi, Yozo Todo
Discovery Research Department, Research Laboratories, Toyama Chemical Co., Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan
Fax: +81(76)4318208; e-Mail: kenichiro_awasaguchi@toyama-chemical.co.jp;

Abstract

Alle Artikel dieser Rubrik

Abstract

We have achieved the synthesis of 1-aryl-2-substituted 4-oxoquinoline and 4-oxo-1,8-naphthyridine derivatives, which cannot be synthesized by known methods, via two useful synthons, 2-formyl-4-oxoquinoline and 2-methylsulfonyl-4-oxo-1,8-naphthyridine. We also succeeded in the synthesis of 1-aryl-3-fluoro-4-oxoquinoline by fluorocyclization of N-arylenaminone with Selectfluor^® and potassium carbonate in DMF in a one-pot procedure. To the best of our knowledge, this is the first synthesis of 3-fluoro-4-oxoquinoline derivatives. We confirmed that these protocols were mutually applicable to the synthesis of 4-oxoquinoline and 4-oxo-1,8-naphthyridine derivatives.

Key words

antiviral agents - heterocycles - HIV - 4-oxoquinoline - 4-oxo-1,8-naphthyridine - fluorocyclization

Volltext

Referenzen

References and Notes

For reviews, see:

<A NAME="RU51611ST-1A">1a</A> Mitscher LA. Chem. Rev. 2005, 105: 559

<A NAME="RU51611ST-1B">1b</A> Andriole VT. The Quinolones 3rd ed.: Academic Press; San Diego: 2000.

<A NAME="RU51611ST-2A">2a</A> Xia Y. Yang Z.-Y. Xia P. Bastow KF. Nakanishi Y. Nampoothiri P. Hamel E. Brossi A. Lee K.-H. Bioorg. Med. Chem. Lett. 2003, 13: 2891

<A NAME="RU51611ST-2B">2b</A> Tsuzuki Y. Tomita K. Shibamori K. Sato Y. Kashimoto S. Chiba K. J. Med. Chem. 2004, 47: 2097

<A NAME="RU51611ST-3A">3a</A> Lucero Bd’A. Gomes CRBV. de Souza TML. Ferreira VF. Bioorg. Med. Chem. Lett. 2006, 16: 1010

<A NAME="RU51611ST-3B">3b</A> Moyer MP. Weber FH. Gross JL. J. Med. Chem. 1992, 35: 4595

<A NAME="RU51611ST-3C">3c</A> Santo RD. Costi R. Roux A. Artico M. Lavecchia A. Marinelli L. Novellino E. Palmisano L. Andreotti M. Amici R. Galluzzo CM. Nencioni L. Palamara AT. Pommier Y. Marchand C. J. Med. Chem. 2006, 49: 1939

<A NAME="RU51611ST-3D">3d</A> Sato M. Motomura T. Aramaki H. Matsuda T. Yamashita M. Ito Y. Kawakami H. Matsuzaki Y. Watanabe W. Yamataka K. Ikeda S. Kodama E. Matsuoka M. Shinkai H. J. Med. Chem. 2006, 49: 1506

<A NAME="RU51611ST-3E">3e</A> Massari S. Daelemans D. Barreca ML. Knezevich A. Sabatini S. Cecchetti V. Marcello A. Pannecouque C. Tabarrini O. J. Med. Chem. 2010, 53: 641

These three compounds having a substituent on the C-2 or C-3 position in Figure [¹] exhibited potent anti-HIV activity in the nanomolar range (IC₅₀ = 0.23-9.2 nM).

An anti-HIV activity was evaluated using MaRBLE cells obtained by transfection of HPB-Ma derived from human T-lymphocytes with a luciferase gene and a CCR5 gene etc. of which expressions were regulated by HIV-1 LTR.

<A NAME="RU51611ST-4C">4c</A> Oonishi Y, Awasaguchi K, Nomura N, Todo K, Kawai H, and Wakatsuki T. inventors; Int. Patent Appl., WO2011090095. For more details, see:

<A NAME="RU51611ST-4D">4d</A> Chiba-Mizutani T. Miura H. Matsuda M. Matsuda Z. Yokomaku Y. Miyauchi K. Nishizawa M. Yamamoto N. Sugiura W. J. Clin. Microbiol. 2007, 45: 447

<A NAME="RU51611ST-5">5</A> For a recent review, see: Kouznetsov VV. Mendez LYV. Gomez MM. Curr. Org. Chem. 2005, 9: 141

<A NAME="RU51611ST-6A">6a</A> Werner W. Tetrahedron 1969, 25: 255

<A NAME="RU51611ST-6B">6b</A> Chen B. Huang X. Wang J. Synthesis 1987, 482

<A NAME="RU51611ST-6C">6c</A> Madrid PB. Sherrill J. Liou AP. Weisman JL. DeRisi JL. Guy RK. Bioorg. Med. Chem. Lett. 2005, 15: 1015

<A NAME="RU51611ST-7">7</A> Camps R. Chem. Ber. 1899, 32: 3228

<A NAME="RU51611ST-8A">8a</A> Huang J. Chen Y. King AO. Dilmeghani M. Larsen RD. Faul MM. Org. Lett. 2008, 10: 2609

<A NAME="RU51611ST-8B">8b</A> Jones CP. Anderson KW. Buchwald SL. J. Org. Chem. 2007, 72: 7968

<A NAME="RU51611ST-9A">9a</A> Sosnovskikh VY. Usachev BI. Sevenard DV. Röschenthaler G.-V. J. Fluorine Chem. 2005, 126: 779

<A NAME="RU51611ST-9B">9b</A> Usachev BI. Sosnovskikh VY. J. Fluorine Chem. 2004, 125: 1393

<A NAME="RU51611ST-9C">9c</A> López SE. Rebollo O. Salazar J. Charris JE. Yánez C. J. Fluorine Chem. 2003, 120: 71

<A NAME="RU51611ST-9D">9d</A> Kim DH. J. Heterocycl. Chem. 1981, 18: 1393

<A NAME="RU51611ST-9E">9e</A> Friary RJ. Seidl V. Schwerdt JH. Cohen MP. Hou D. Nafissi M. Tetrahedron 1993, 49: 7169

<A NAME="RU51611ST-10">10</A> Bernini R. Cacchi S. Fabrizi G. Sferrazza A. Synthesis 2009, 1209

<A NAME="RU51611ST-11">11</A> Zhao T. Xu B. Org. Lett. 2010, 12: 212

<A NAME="RU51611ST-12">12</A> Radl S. Obadalova I. Collect. Czech. Chem. Commun. 2004, 69: 822

Analytical and Spectral Data of N -Arylenaminone 5: pink solid; mp 112-113 ˚C. ^¹H NMR (400 MHz, CDCl₃): δ = 7.75 (dd, J = 8.3, 8.0 Hz, 1 H), 7.36 (dd, J = 8.3, 1.7 Hz, 1 H), 7.29 (dd, J = 10.4, 1.7 Hz, 1 H), 7.22 (ddd, J = 8.8, 8.5, 5.8 Hz, 1 H), 6.88-6.98 (m, 2 H), 5.89 (d, J = 2.2 Hz, 1 H), 2.02 (s, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 184.6 (d, J = 4.1 Hz), 163.8, 161.1 (dd, J = 249.6, 10.8 Hz), 160.1 (d, J = 256.2 Hz), 157.0 (dd, J = 250.4, 12.4 Hz), 131.7 (d, J = 3.3 Hz), 128.5 (d, J = 9.1 Hz), 127.7 (d, J = 3.3 Hz), 127.2 (d, J = 13.2 Hz), 125.1 (d, J = 9.9 Hz), 122.6 (dd, J = 13.2, 4.1 Hz), 119.8 (d, J = 27.2 Hz), 111.6 (dd, J = 22.3, 4.1 Hz), 104.9 (dd, J = 26.0, 24.4 Hz), 98.6 (d, J = 10.7 Hz), 19.8 (d, J = 2.5 Hz). IR (neat): 1590, 1568, 1541, 1433, 1395, 1318, 1304, 1283, 1094, 882, 857, 778 cm^-¹. HRMS (DART):
m/z [M + H]⁺ calcd for C₁₆H₁₂BrF₃NO: 370.00544; found: 370.00546.

<A NAME="RU51611ST-14">14</A> Rudorf W.-D. Schierhorn A. Augustin M. Tetrahedron 1979, 35: 551

In a synthesis of 4-oxoquinoline derivatives, enolate formation of 2,4-dichloroacetophenone was conducted with t-BuOK as a base in THF at r.t. to give a good result of obtaining ketene-S,N-acetal.

When 4-bromo-2-fluoro-acetophenone (1) was used as a starting material, 2-anilino-7-bromo-1-thiochromone was produced via the same synthetic protocol.

<A NAME="RU51611ST-16">16</A> Barder TE. Walker SD. Martinelli JR. Buchwald SL. J. Am. Chem. Soc. 2005, 127: 4685

<A NAME="RU51611ST-17">17</A> For a review of recent highlights, see: Singh RP. Shreeve JM. Acc. Chem. Res. 2004, 37: 31

General Procedure for the Synthesis of Aldehyde 3: To a solution of 1-aryl-2-methyl-4-oxoquinoline 2 (1.58 g, 4.51 mmol) in 1,4-dioxane (18 mL) was added selenium dioxide (0.53 g, 4.51 mmol) at r.t. The mixture was heated under reflux for 4 h. The solvent was concentrated in vacuo, then the residue was diluted with EtOAc and the suspension was filtered. The filtrate was washed with sodium thiosulfate solution and brine, dried over MgSO₄, filtered and concen-trated in vacuo. The residue was subjected to silica gel column chromatography (hexane-EtOAc, 2:1 → 1:1, gradient) to afford aldehyde 3 (0.99 g, 60% yield) as a pale yellow solid. Analytical and Spectral Data of Aldehyde 3: pale yellow solid; mp 195-196 ˚C. ^¹H NMR (400 MHz, DMSO-d ₆): δ = 9.64 (s, 1 H), 8.16 (d, J = 8.5 Hz, 1 H), 7.75 (ddd, J = 8.9, 8.9, 6.0 Hz, 1 H), 7.68 (dd, J = 8.5, 1.7 Hz, 1 H), 7.64-7.72 (m, 1 H), 7.36-7.42 (m, 1 H), 7.01 (br s, 1 H), 6.97 (s, 1 H). ^¹³C NMR (100 MHz, DMSO-d ₆): δ = 188.4, 177.3, 163.0 (dd, J = 250.0, 12.0 Hz), 158.3 (dd, J = 250.9, 13.6 Hz), 143.9, 142.7, 132.2 (d, J = 10.7 Hz), 128.2, 127.9, 127.8, 125.2, 121.1 (dd, J = 13.2, 4.1 Hz), 119.4, 118.5, 113.3 (dd, J = 22.3, 3.3 Hz), 105.7 (dd, J = 26.9, 23.6 Hz). IR (neat): 1702, 1631, 1595, 1512, 1448, 1271, 1149, 1008, 972, 947, 856, 830 cm^-¹. HRMS (DART): m/z [M + H]⁺ calcd for C₁₆H₉BrF₂NO₂: 363.97847; found: 363.97898.

General Procedure for the Synthesis of Ketene- S , N -acetal 8: To a solution of 3-acetyl-2,6-dichloropyridine (7) in THF (26 mL) was added lithium diisopropylamide (2.0 M, 3.0 mL, 6.05 mmol) dropwise at -40 ˚C under nitrogen atmosphere. After stirring at -40 ˚C for 30 min, to the mixture was added a solution of 2,6-difluorophenyl isothiocyanate (2.08 g, 12.1 mmol) in THF (11 mL). The mixture was gradually warmed up to r.t. while stirring for 1.5 h. After stirring, the mixture was cooled in an ice bath. To the mixture was added iodomethane (0.75 mL, 12.1 mmol) at 5 ˚C and the mixture was warmed up to r.t. while stirring for 20 min. The reaction was quenched with sat. NH₄Cl solution at 5 ˚C and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane-EtOAc, 20:1 → 10:1, gradient) to afford ketene-S,N-acetal 8 (0.66 g, 35% yield) as a pale yellow solid. Analytical and Spectral Data of Ketene- S , N -acetal 8: pale yellow solid; mp 164-165 ˚C. ^¹H NMR (400 MHz, CDCl₃): δ = 12.78 (br s, 1 H), 7.91 (d, J = 8.1 Hz, 1 H), 7.41 (ddd, J = 8.7, 8.7, 5.9 Hz, 1 H), 7.35 (d, J = 8.1 Hz, 1 H), 6.90-7.00 (m, 2 H), 5.70 (s, 1 H), 2.41 (s, 3 H). ^¹³C NMR (100 MHz, CDCl₃): δ = 183.6, 170.5, 161.7 (dd, J = 250.4, 10.8 Hz), 157.3 (dd, J = 252.5, 12.8 Hz), 150.5, 146.7, 141.0, 135.6, 129.4 (d, J = 10.7 Hz), 123.1, 121.8 (dd, J = 12.4, 4.1 Hz), 111.5 (dd, J = 22.3, 4.1 Hz), 105.0 (dd, J = 26.5, 24.0 Hz), 92.9, 14.7. IR (neat): 1575, 1512, 1468, 1411, 1260, 1143, 1045, 966, 846, 730 cm^-¹. HRMS (DART): m/z [M + H]⁺ calcd for C₁₅H₁₁Cl₂F₂N₂OS: 374.99372; found: 374.99405.

General Procedure for the Synthesis of 1-Aryl-3-fluoro-4-oxoquinoline 15: To a solution of N-arylenaminone 14 (100 mg, 0.28 mmol) in DMF (2.8 mL) was added Selectfluor^® (149 mg, 0.42 mmol) at r.t. The mixture was stirred for 30 min at the same temperature. To the mixture was added K₂CO₃ (116 mg, 0.84 mmol) and the mixture was heated to 80 ˚C. After stirring for 30 min at 80 ˚C, the mixture was cooled and diluted with EtOAc and H₂O. The organic layer was washed with brine, dried over MgSO₄, filtered and concentrated in vacuo. The residue was subjected to silica gel column chromatography (hexane-EtOAc, 3:1) to afford 1-aryl-3-fluoro-4-oxoquinoline 15 (38 mg, 38% yield) as a pale yellow solid. Analytical and Spectral Data of 1-Aryl-3-fluoro-4-oxoquinoline 15: pale yellow solid; mp 197-198 ˚C. ^¹H NMR (400 MHz, DMSO-d ₆): δ = 8.66 (d, J = 8.3 Hz, 1 H), 8.24 (d, J = 8.6 Hz, 1 H), 7.89 (ddd, J = 8.8, 8.8, 5.9 Hz, 1 H), 7.69-7.76 (m, 1 H), 7.64 (dd, J = 8.6, 1.6 Hz, 1 H), 7.40-7.46 (m, 1 H), 7.17 (s, 1 H). ^¹³C NMR (100 MHz, DMSO-d ₆): δ = 167.8 (d, J = 14.9 Hz), 162.9 (dd, J = 249.6, 11.6 Hz), 157.7 (dd, J = 252.5, 13.6 Hz), 146.6 (d, J = 238.0 Hz), 140.6, 132.0 (d, J = 28.9 Hz), 131.7 (d, J = 3.3 Hz), 127.8 (d, J = 4.1 Hz), 127.2, 126.6, 125.4 (d, J = 9.9 Hz), 123.5 (dd, J = 12.8, 3.7 Hz), 119.1, 113.4 (dd, J = 22.7, 3.7 Hz), 106.0 (dd, J = 27.3, 23.1 Hz). IR (neat): 1624, 1587, 1509, 1328, 1217, 1193, 1143, 1101, 968, 926, 853, 834, 772 cm^-¹. HRMS (DART): m/z [M + H]⁺ calcd for C₁₅H₈BrF₃NO: 353.97414; found: 353.97405.